These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28591560)

  • 1. Implications of the lysophosphatidic acid signaling axis in liver cancer.
    Lopane C; Agosti P; Gigante I; Sabbà C; Mazzocca A
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):277-282. PubMed ID: 28591560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
    Park SY; Jeong KJ; Panupinthu N; Yu S; Lee J; Han JW; Kim JM; Lee JS; Kang J; Park CG; Mills GB; Lee HY
    Oncogene; 2011 Mar; 30(11):1351-9. PubMed ID: 21102517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.
    Kaffe E; Magkrioti C; Aidinis V
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophospholipid variants in hepatocellular carcinoma.
    Skill NJ; Jianmin W; Yan X; Zhao Z; Tector AJ; Maluccio MA
    J Surg Res; 2013 Jun; 182(2):241-9. PubMed ID: 23158405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
    Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
    Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor.
    Lou L; Chen YX; Jin L; Li X; Tao X; Zhu J; Chen X; Wu S; Ye W; He J; Ding G
    J Int Med Res; 2013 Feb; 41(1):55-63. PubMed ID: 23569130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway.
    Zhu B; Shi S; Ma YG; Fan F; Yao ZZ
    Hepatogastroenterology; 2012 May; 59(115):785-9. PubMed ID: 22020916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
    Agosti P; Sabbà C; Mazzocca A
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma associated lipid metabolism reprogramming.
    Skill NJ; Scott RE; Wu J; Maluccio MA
    J Surg Res; 2011 Jul; 169(1):51-6. PubMed ID: 19932908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis.
    Xia Q; Deng AM; Wu SS; Zheng M
    Acta Pharmacol Sin; 2011 Aug; 32(8):1055-62. PubMed ID: 21765444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma.
    Chettouh H; Lequoy M; Fartoux L; Vigouroux C; Desbois-Mouthon C
    Liver Int; 2015 Oct; 35(10):2203-17. PubMed ID: 26123841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.
    Enooku K; Uranbileg B; Ikeda H; Kurano M; Sato M; Kudo H; Maki H; Koike K; Hasegawa K; Kokudo N; Yatomi Y
    PLoS One; 2016; 11(9):e0161825. PubMed ID: 27583415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.
    Erstad DJ; Tager AM; Hoshida Y; Fuchs BC
    Mol Cell Oncol; 2017; 4(3):e1311827. PubMed ID: 28616586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid aberrancies and hepatocellular carcinoma: studies in the MDR2 gene knockout mouse.
    Skill N; Wu J; Xu Y; Zhao Z; Maluccio M
    Cancer Invest; 2013 Feb; 31(2):145-55. PubMed ID: 23362952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin in liver fibrosis.
    Ikeda H; Yatomi Y
    Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
    Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
    BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades.
    Zhang R; Cao Y; Bai L; Zhu C; Li R; He H; Liu Y; Wu K; Liu F; Wu J
    Mol Carcinog; 2015 Dec; 54(12):1554-66. PubMed ID: 25263696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
    Sokolov E; Eheim AL; Ahrens WA; Walling TL; Swet JH; McMillan MT; Simo KA; Thompson KJ; Sindram D; McKillop IH
    J Surg Res; 2013 Mar; 180(1):104-13. PubMed ID: 23182454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.